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SUMMARY 
 
Cancer control by adaptive immunity involves numerous death1-8 and 
clearance9-11 mechanisms. Yet, efficient inhibition of exponential cancer growth 
by T-cells and interferon-γ (IFN-γ) strictly requires additional, so far undefined 
mechanisms that arrest cancer cell proliferation1-5,12,13. Here we show that the 
combined action of the T-helper 1 (TH1)-cell cytokines IFN-γ and tumor-necrosis-
factor (TNF) directly induces permanent growth arrest in cancers. To safely 
separate senescence induced by tumor-immunity from oncogene-induced 
senescence9-11,14-17, we used RIP1-Tag2 mice, where large T-antigen (Tag) 
causes cancer by attenuating p53- and Rb-mediated cell cycle control18,19. When 
combined, IFN-γ and TNF drive Tag-expressing cancers into senescence, as 
they induce permanent growth arrest in G1/G0, activation of p16Ink4a, downstream 
Rb-hypophosphorylation at Ser795, and E2F2 suppression. This cytokine-
induced senescence strictly requires STAT1- and TNFR1-signaling. Also in vivo, 
Tag-specific TH1-cells permanently arrest Tag-expressing cancers by inducing 
IFN-γ- and TNFR1-dependent senescence. Therefore, TNFR1-/-xRIP1-Tag2 
cancers resist to cytokine-induced senescence and grow aggressively, even in 
TNFR1-expressing hosts. Moreover, IFN-γ and TNF induce senescence in 
murine breast cancers and human rhabdomyosarcoma, revealing IFN-γ/TNF -
induced senescence as a general mechanism arresting cancer progression. 
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Recent studies from targeted cancer immunotherapies show that adaptive immunity 
can efficiently control human cancer20-24. Surprisingly, many cancer immunotherapies 
do not cause cytotoxic cancer elimination but arrest cancer growth or induce slow 
cancer regression21,22, even though immunotherapies generally focus on CD8+ 
cytotoxic T lymphocytes (CTL) or natural killer cells1-8,23,24. Moreover, where studied, 
growth arrest and cancer regression correlate with tumor-specific, IFN-γ producing 
CD4+ (TH1) cells rather than CTL20-23. In addition, profiling of patients in clinical cancer 
trials shows a critical role for IFN-γ and TNF in cancer control25,26. 
Similarly, efficient immune control of murine cancers resulting from aberrant cell 
cycle control, oncogene expression, chemical or viral transformation strictly requires 
IFN-γ3-7,12,27. In consequence, IFN-γ- and TNF-producing TH1 cells specific for the 
tumor antigen Tag (Tag-TH1) restrain Tag-induced islet cancers in mice expressing 
Tag under the control of the rat insulin promotor1 (RIP1-Tag2) in all pancreatic islet 
cells12,18. TH1-immunity doubles life span of mice through strictly IFN-γ- and TNFR1-
dependent mechanisms12, without causing detectable signs of cytotoxicity, tumor cell 
necrosis, or apoptosis12. This is surprising, as Tag-expression causes invasive β-cell 
cancers (β-cancer) in 2% of the islets by incomplete retinoblastoma (Rb) suppression 
and p53 silencing18,19. 
Only CD4+ TH1 cells that produce IFN-γ and TNF and that are specific for Tag-
peptide (Tag-TH1 cells), induce IFN-γ- and TNFR1-dependent arrest of RIP1-Tag2 
cancers (Supplementary Fig. 1a-c)12. This arrest occurs in the absence of significant T 
cell infiltration (Supplementary Fig. 1c, 2)12 and is independent of either CTL12 or 
enhanced apoptosis, as determined by TUNEL12 or caspase-3 staining. Instead, Tag-
specific TH1 cells form follicle-like structures around the islets, where they interact with 
antigen-presenting cells12. Ki67 staining confirmed that Tag-TH1 cells arrested 
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proliferation of β-cancers in vivo (Supplementary Fig. 3a). Freshly isolated β-cancer 
cells from Tag-TH1 cell-treated RIP1-Tag2 mice failed to proliferate in vitro while β-
cancer cells from sham-treated mice strongly incorporated 3H-thymidine 
(Supplementary Fig. 3b). This suggests that TH1 cytokines induce senescence in vivo, 
despite normal Tag-expression (Supplementary Fig. 4). 
To directly ask whether IFN-γ and TNF induce senescence in β-cancers, we 
cultured freshly isolated β-cancer cells from sham-treated mice with either medium or 
with IFN-γ and TNF. In cell cycle analysis, untreated β-cancer cells were ≥25% in S 
phase and 40% in G1/G0, explaining their rapid proliferation. When combined, IFN-γ 
and TNF arrested most β-cancer cells in G1/G0 within three days (Fig. 1a). They 
reduced S phase cells to 3% and increased the G1/S ratio 20-fold (Fig. 1b) without 
increasing the apoptotic sub-G1 fraction (Fig. 1a). As IFN-γ and TNF arrested the β-
cancer cells in G1/G0, a state characterizing cellular senescence, we asked whether 
IFN-γ and TNF caused senescence-defining permanent growth arrest.  
Freshly isolated β-cancer cells proliferated rapidly in medium. When cultured 
in the presence of IFN-γ and TNF, β-cancer cells were fully growth arrested (Fig. 1c). 
To determine whether the growth-arrested β-cancer cells were really senescent, we 
washed the cells on day five and cultured them for another two weeks with medium 
only. While untreated β-cancer cells continued to expand, β-cancer cells that had 
been exposed for five days to the combination of IFN-γ and TNF were truly senescent 
as they remained fully growth-arrested (Fig. 1c). Even two weeks after withdrawal of 
IFN-γ and TNF, the β-cancer cells failed to incorporate BrdU while untreated controls 
strongly incorporated BrdU (Fig. 1d, e, Supplementary Fig. 5a, b).  
IFN-γ and TNF also induced the characteristic senescence-associated 
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epigenetic and lysosomal changes, like nuclear recruitment of phosphorylated 
heterochromatin protein 1γ (pHP1γ) into senescence-associated heterochromatin foci 
(SAHF) or senescence-associated β-galactosidase (SA-β-gal) activity. Time course 
studies revealed that within three days, IFN-γ and TNF induced the early senescence 
marker pHP1γ in 75% (Supplementary Fig. 6a, b) and SA-β-gal in 50% of the β-
cancer cells (Fig. 2a, b). Yet, induction of stable growth arrest and the late 
senescence marker SA-β-gal in 80% of the cells (Fig. 2c) needed ≥4 days of 
incubation with both IFN-γ and TNF. Double-staining with synaptophysin, an islet cell 
marker, confirmed SA-β-gal-expression by β-cancer cells (Supplementary Fig. 7). 
Combined IFN-γ and TNF established the senescence-defining permanent growth 
arrest in β-cancers cells while neither IFN-γ nor TNF alone was sufficient to induce 
full growth arrest (Supplementary Fig. 5a, b), although inducing early signs of 
senescence such as pHP1γ recruitment to SAFH (Supplementary Figure 6a, b), and 
SA-β-gal in 20% of the cells (Fig. 2b). 
 As combined stimulation of islets or islet tumors with IFN-γ and TNF strongly 
induces JunB28, the combined IFN-γ/STAT1- and TNFR1-signaling may activate the 
JunB downstream target p16Ink4a and thus stabilize the p16Ink4a/Rb senescence 
pathway in Tag-expressing β-cancers. Indeed, IFN-γ and TNF strongly induced 
p16Ink4a in subconfluent cultures within 48 hours (Fig. 2d), while p16Ink4a remained 
weakly expressed in medium-treated, subconfluent β-cancer cells (Fig. 2d). As this 
induction of p16Ink4a also caused sustained and severe hypophosphorylation of Rb at 
Ser795 (Fig. 2e) and suppressed the Rb-regulated gene E2F215 down to 20%, IFN-γ 
and TNF conjointly stabilized the p16Ink4a/Rb senescence pathway in β-cancer cells. 
In line with this, STAT1- or TNFR1-deficient β-cancer cells fully resisted senescence 
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induction by IFN-γ and TNF, underlining that hypophosphorylation of Rb strictly 
required the combined action of the STAT1- and TNFR1-signaling pathways (Fig. 2b, 
f). As IFN-γ and TNF also induced senescence in unrelated breast cancers from 
polyoma virus middle T antigen (PyVmT)-transgenic mice (Supplementary Fig. 8) or 
human A204 rhabdomyosarcoma cells (Supplementary Fig. 9), cytokine-induced 
senescence was not restricted to Tag-expressing cancers. 
 Combined IFN-γ- and TNFR1-signaling is also necessary to arrest β-cancers in 
vivo12 (Supplementary Fig. 1). Together the in vitro and in vivo data thus suggest that 
TH1-immunity arrested cancer progression through IFN-γ- and TNF-induced 
senescence in vivo. To test this hypothesis, we first quantified senescence-
associated chromatin changes by counting cancer cells positive for pHP1γ, 
trimethylated lysine-9 of histone 3 (H3K9me3), or apoptosis-associated active 
caspase-3 by immunohistology in either sham-treated mice or mice treated with Tag-
TH1 cells. TH1-immunity significantly increased pHP1γ− and H3K9me3-positive nuclei 
in β-cancers, but not caspase-3-positive cells (Fig. 3a, b).  
To address whether TH1-immunity activated the p16Ink4a/Rb pathway also in 
vivo, we double-stained sections for p16Ink4a and the proliferation marker Ki67. In 
sham-treated mice, the β-cancer cells were ≥30% Ki67-positive and only 5% p16Ink4a-
positive. TH1-immunity diminished Ki67+ cells to 3%, and increased the fraction of 
p16Ink4a-positive cells (nuclear and cytoplasmic) to ≥20% (Figure 3c, d, 
Supplementary Fig. 10).  
Senescence-induction by TH1-immunity strictly required TNFR1-signaling also 
in vivo. TNFR1-/- β-cancers failed to increase either pHP1γ, H3K9me3, or active 
caspase-3 when treated with Tag-TH1 cells (Supplementary Fig. 11a, b). In addition, 
whether isolated from sham- or Tag-TH1 cell-treated mice, TNFR1-deficient β-cancer 
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cells expressed Ki67 but not p16Ink4a (Fig. 3c, d), even though Tag-TH1 cells migrate 
into pancreata of TNFR1-/-xRIP1-Tag2 mice12. As TH1-immunity severely impaired  β-
cancer growth in vivo12, these data strongly suggest that the combined IFN-γ- and 
TNFR1-signaling drove cancers into senescence also in vivo. Yet, the most stringent 
criterion defining senescence is stable and permanent growth arrest in the absence 
of TH1-immunity9,15-17.  
We therefore cultured freshly isolated β-cancer cells from 12-week-old mice 
with medium only. Cells from sham-treated RIP1-Tag2 mice first suffered a critical 
loss and then re-initiated proliferation, yielding 10-20x105 β-cancer cells/pancreas 
after three passages (Fig. 4a). In contrast, β-cancer cells from RIP1-Tag2 mice 
treated with Tag-TH1 cells were truly senescent, as they failed to proliferate over 
three passages and stably yielded only 0.5-2.0x105 cells/pancreas (Fig. 4a). β-cancer 
cells from TNFR1-/-xRIP1-Tag2 mice grew exponentially also in vitro, yielding 
100x105 cells within three passages, even when derived from Tag-TH1 cell-treated 
mice (Fig. 4a).   
To determine whether senescence was also maintained in vivo, we re-
implanted the four different β-cancer cell lines after the 3rd passage under the skin of 
NOD-SCIDxIL2Rcγ-/- mice, as growth at ectopic sites characterizes cancers2. Within 
seven weeks, as few as 1.2x105 β-cancer cells from sham-treated RIP1-Tag2 mice 
significantly decreased blood glucose (Fig. 4b) and increased the serum insulin levels 
(Fig. 4c), demonstrating the metastatic potential of β-cancer cells from sham-treated 
mice. Senescent β-cancers from RIP1-Tag2 mice treated with Tag-TH1 cells 
remained growth-arrested also in vivo, as blood glucose remained stable in all 
transplanted mice throughout the seven weeks (Fig. 4b). Minute adenomas in some 
NOD-SCIDxIL2Rcγ-/- mice and marginally increased serum insulin (Fig. 4c) showed 
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that the transplanted cells survived but remained growth-arrested for ≥10 weeks of in 
vitro and in vivo culture. Again, senescence-resistant TNFR1-/-xRIP1-Tag2 β-cancer 
cells grew rapidly after transplantation and as little as 1.2x105 TNFR1-/- xRIP1-Tag2 
cancer cells rapidly decreased blood glucose (Fig. 4b), irrespective of whether they 
were derived from sham-treated or Tag-TH1 cell-treated mice. Transplanting 60% of 
total β-cancer cells from sham-treated RIP1-Tag2 mice generated tumors within 
seven weeks, while β-cancer cells from Tag-TH1 cell-treated mice failed to grow (Fig. 
4d). Only 10% of β-cancer cells from sham- or Tag-TH1 cell-treated TNFR1-/-xRIP1-
Tag2 mice generated large tumors within the same time (Fig. 4d). 
Oncogenes, DNA-damage or chemotherapeutics induce senescence that, in 
human cells, is reinforced by the senescence-associated secretome14-17,29,30. 
Uncovering that adaptive TH1-immunity directly restrains cancer proliferation through 
IFN-γ/TNF-induced cancer cell senescence provides a long-searched direct 
mechanism explaining the anti-proliferative effects of TH1-immunity on cancers2,3. 
TH1-immunity has thus two majors effects on cancer, it can directly drive cancers into 
senescence and, subsequently, clear senescent cancer cells9-11. As these combined 
effects explain the therapeutic efficiency of tumor-specific TH1-immunity in early 
cervical cancer21 and disseminated melanoma20, TH1 cytokine-induced senescence 
may be of broad relevance for cancer control, also in humans under therapeutic 
conditions.  
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METHODS SUMMARY 
RIP1-Tag2 and TNFR1-/-xRIP1-Tag2 mice were either sham-treated or treated with 
Tag2-specific TH1 cells starting at week 6. Cancer cells were isolated by consecutive 
collagenase/trypsin digestion from tumor tissues of RIP1-Tag2, STAT1-/-xRIP1-Tag2, 
TNFR1-/-xRIP1-Tag2, or PyVmT-transgenic mice. Isolated β-cancer cells were 
identified by immunofluorescence using anti-synaptophysin (early β-cell marker) 
antibodies. Proliferation in vivo and in vitro of tumor cells was measured by BrdU 
incorporation, Ki67 staining, 3H-thymidine incorporation, or cell cycle analysis. 
Senescence was assessed by SA-β-gal staining, immunofluorescence, 
immunohistochemistry or Western blot using anti-pHP1-γ, anti−p16Ink4a, anti-Rb, anti-
phospho-Rb, or anti-H3K9me3 antibodies, or by in vitro and in vivo growth assays. 
Apoptosis was determined by cell cycle analysis, or immunohistochemistry with an 
anti-active caspase 3 antibody. For transfer experiments, β-cancer cells from sham- 
or TH1 cell-treated mice (either RIP1-Tag2 or TNFR1-/-x RIP1-Tag2) were injected 
subcutaneously into NOD-SCIDxIL2Rcγ-/- mice, and tumor growth was monitored with 
a caliper and by measuring blood glucose and insulin levels. 
 
Full methods and any associated references are available in the online version of 
the paper at www.nature.com/nature.  
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Figure Legends 
 
Fig. 1 | Combined, the TH1 cytokines IFN-γ and TNF induce stable growth arrest 
of Tag-driven β-cancer cells in vitro.  
a, b, Cell cycle analysis (a) and mean G1/S ratio (b) of β-cancer cells cultured either 
in the absence or presence of IFN-γ and TNF. c-e, Cell numbers (c), BrdU 
incorporation (d) and mean numbers of BrdU-positive spots (e) of β-cancer cells 
treated for five days with medium only or with IFN-γ and TNF. Thereafter, cells were 
washed and then cultured with medium in the absence of cytokines for another two 
passages. After the second passage 3,000 viable cells were seeded in 96 well plates 
and cell proliferation was analyzed by BrdU staining.   
*P<0.05. n=3-6 (b, c, e). Control=Co. (a-e).  
 
Fig. 2 | STAT1- and TNFR1-dependent stabilization of the p16Ink4a/Rb 
senescence pathway in β-cancer cells by the combined action of IFN-γ and TNF 
in vitro. 
a, SA-β-gal activity of β-cancer cells after 72 h of treatment with medium, IFN-γ, TNF, 
or IFN-γ and TNF. Bar, 100 µm. b, Concentration-dependent induction of SA-β-gal+ 
cells by TNF either in the absence or presence of IFN-γ within 72 h in β-cancer cells 
from RIP1-Tag2 or TNFR1-/-xRIP1-Tag2 mice. c, Induction of SA-β-gal activity by 
IFN-γ and TNF within 96 h. d, Detection of p16Ink4a or β-actin by Western blot in β-
cancer cells treated with medium or with IFN-γ and TNF. e, Detection of 
phosphorylated Rb (p-Rb), total Rb (Rb), or β-actin by Western blot in β-cancer cells 
treated with medium or IFN-γ and TNF. f, SA-β-gal activity of β-cancer cells isolated 
from either RIP1-Tag2 or STAT1-/-xRIP1-Tag2 mice after 72 h of treatment with 
medium or with IFN-γ and TNF. 
*P<0.05. n=3-9 (b,c,f). Control=Co. (a, c-f).  
 
 
Fig. 3 | TNFR1-dependent induction of growth arrest and senescence in β-
cancer cells by TH1-immunity in vivo.  
a, b, Analysis of the senescence markers pHP1γ and tri-methylated H3K9 
(H3K9me3), or the apoptosis marker active caspase-3 by immunohistochemistry (a), 
and percentage (b) of pHP1γ-, H3K9me3- or active caspase-3-positive cells in β-
cancers from RIP1-Tag2 mice that were either sham- or Tag-TH1 cell-treated. Bar, 
100 µm. c, d, Double-staining (c) for the senescence marker p16Ink4a (red) and the 
proliferation marker Ki67 (blue), and percentage (d) of p16Ink4a- and Ki67-positive 
cells in cancers from RIP1-Tag2 or TNFR1-/-xRIP1-Tag2 mice that were sham- or 
Tag-TH1 cell-treated. Nuclei are green. Bar, 25 µm.  
*P<0.05 from sham-treated control. n=5-6 (b, d).  
 
Fig. 4 | TH1-immunity induces TNFR1-dependent, permanent growth arrest of β-
cancer cells which remains stable for ≥10 weeks, even after transfer into 
immune-deficient NOD-SCIDxIL2Rcγ-/- mice. 
a, Cell numbers of β-cancer cells isolated from RIP1-Tag2 or TNFR1-/-xRIP1-Tag2 
mice that were sham- or Tag-TH1 cell-treated. The number of cell passages (p) is 
indicated, and the data are presented as number of living β-cancer cells per mouse. 
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b, Blood glucose levels in NOD-SCIDxIL2Rcγ-/- mice after transfer of 1.2x105 β-
cancer cells isolated from sham- or Tag-TH1 cell-treated RIP1-Tag2 or TNFR1-/-
xRIP1-Tag2 mice. c, Insulin levels in NOD-SCIDxIL2Rcγ-/- mice after transfer of 
1.2x105 β-cancer cells isolated from sham- or Tag-TH1 cell-treated RIP1-Tag2 mice. 
d, Tumor volumes in NOD-SCIDxIL2Rcγ-/- mice after transfer of β-cancer cells 
isolated from sham- or Tag-TH1 cell-treated mice. The table indicates origin and 
percentage of total β-cancer cells/mouse injected.  
Red lines: blood glucose of untreated NOD-SCIDxIL2Rcγ-/- mice (b). Dashed red 
lines: normal range of insulin in healthy mice (c).  
*P<0.05 from sham-treated control. n=3-6 (a-d). 
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METHODS 
Animals. C3H mice from Charles River (Sulzberg, Germany), transgenic RIP1-Tag2 
mice31, double transgenic TNFR1-/-xRIP1-Tag212, 32 and STAT1-/-xRIP1Tag2 mice 
(backcross of STAT-/- mice from Taconic (Hudson, NY, USA) over 12 generations to 
C3H), TCR2 mice33 all on a C3H background, and PyVmT-transgenic mice34 were 
bred under specific pathogen-free conditions. NOD-SCIDxIL2Rcγ-/- mice (NOD.Cg-
Prkdcscid IL2rcγtm1Wjl/SzJ)35 were from The Jackson Laboratory (Bar Harbor, ME, 
USA). Animal experiments were approved by the local authorities (HT 2/03, HT2/07 
and K1/07). 
Cell culture and single cell analysis. Tag-specific TH1 cells were isolated and 
generated from TCR2 mice, and characterized by flow cytometry12.  
Tumors were isolated from sham- and Tag-TH1-cell-treated RIP1-Tag2 mice, sham- 
and Tag-TH1-cell-treated TNFR1-/-xRIP1-Tag2 mice, STAT1-/-xRIP1-Tag2 mice, or 
mammary tumor-bearing PyVmT-transgenic mice by collagenase digestion (1 mg/ml, 
Serva, Heidelberg, Germany) for 10 min at 37°C, and then separated under a 
dissection microscope (Leica Microsystems, Wetzlar, Germany). Tumor cells were 
obtained by incubation in 0.05% trypsin/EDTA solution (Invitrogen, Darmstadt, 
Germany) at 37°C for 10 min, and seeded on tissue culture plates. Adherent cells 
were cultured for 2 to 5 weeks in RPMI 1640 supplemented with 10% fetal calf 
serum, nonessential amino acids, antibiotics, and 50 µM 2-mercaptoethanol at 37°C 
and 5% CO2. Human rhabdomyosarcoma cells (A204 cells) were grown in complete 
RPMI 1640 medium. If not otherwise stated, subconfluent cells were treated with 100 
ng/ml mouse or human IFN-γ (R&D Systems, Wiesbaden, Germany), or 10 ng/ml 
mouse or human TNF (R&D Systems), or with a combination of mouse or human 
IFN-γ (50-100 ng/ml) and mouse or human TNF (0.1-10 ng/ml) for 2-6 d. β-cancer 
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cells were identified by immunofluorescence using an anti-synaptophysin antibody 
(undiluted; Lifespan Biosciences, Seattle, WA, USA). 
In vitro proliferation assays. After treatment, cancer cell proliferation was 
measured either by the [3H]-thymidine incorporation assay36, or by the BrdU-based 
Cell Proliferation ELISA and XTT-based Cell Proliferation Kit II according to the 
manufacturer´s protocols (Roche Diagnostics, Mannheim, Germany). [3H]-thymidine 
incorporation was quantified using a MicroBeta TriLux counter (PerkinElmer, 
Rodgau, Germany), and colorimetric analyses were performed on a Multiskan EX 
microplate reader (Thermo Electron, Erlangen, Germany).       
In vitro growth arrest assays. The different cancer cells were seeded at a density 
of 1 x 104 cells/cm2. Then, the cells were treated with control medium or cytokines as 
described above for 4-5 d. After treatment, the cells were trypsinized and viable cells 
(trypan blue exclusion) were counted under a Zeiss Axiovert 25 microscope (Zeiss, 
Oberkochen, Germany)  using a Neubauer counting-chamber (Karl Hecht GmbH, 
Sondheim, Germany). The cells were seeded at 2 x 104 cells/cm2 and grown in 
complete RPMI 1640 medium until the control cultures reached confluence. Then, 
the cells were trypsinized, counted and seeded again. After passage 1-2 (p1-p2), 
1000-3000 viable cells were seeded on MultiscreenTM HTS 96 well Filtration Plates 
(Millipore, Billerica, MA, USA), and proliferation was measured by the BrdU-based 
Cell Proliferation ELISA (Roche Diagnostics) in combination with the Vector®SG 
Substrate Kit for Peroxidase from Vector Laboratories (Burlingame, CA, USA) to 
visualize BrdU-incorporating cells. BrdU-positive spots were counted with an 
ELISPOT reader (Bioreader®-3000; BIO-SYS, Karben, Germany). In addition, some 
cultures were stained with DAPI (Invitrogen) to visualize the nuclei of adherent cells. 
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Treatment of mice with Tag-TH1 cells. Before the first Tag-TH1-cell-based therapy, 
all mice received 2 Gy total-body irradiation. Then, 1 x 107 Tag-TH1 cells in 0.9% 
NaCl solution (Tag-TH1) or NaCl solution alone (Sham) was injected intraperitoneally 
once per week starting at week 612. If not otherwise stated, mice were sacrificed at 
week 12.   
Transfer of β-cancer cells into immune-deficient mice. β-cancer cells isolated 
from the various groups of mice were cultured for 3 passages. Then, 10-60% of the 
β-cancer cells were injected subcutaneously (s.c.) into immune-deficient NOD-
SCIDxIL2Rcγ-/- mice. Tumor growth was monitored with a caliper, and blood glucose 
was measured using an Accu-Check sensor (Roche Diagnostics) for up to 7 weeks. 
Serum insulin levels were determined using the rat/mouse insulin ELISA kit from 
Millipore.    
Immunofluorescence and immunohistochemistry. The different cancer cells were 
grown on chamber slides (BD Biosciences, Heidelberg, Germany). After treatment, 
the cells were fixed with acetone/methanol 1:1. The slides were washed with 
PBS/0.05% Tween 20 at room temperature (RT), blocked with serum-free DAKO-
Block (DAKO, Hamburg, Germany), washed again, and then incubated with the 
following antibodies: anti-Ki67 (dilution 1:100; Abcam, Cambridge, UK), anti-PCNA 
(dilution 1:100; Cell Signaling Technology, Boston, MA, USA), anti-pHP1γ (dilution 
1:100; Abcam), anti-H3K9me3 (dilution 1:500; Millipore, Schwalbach, Germany), anti-
p16Ink4a (dilution 1:100; Santa Cruz Biotechnology, Heidelberg, Germany), anti-SV40 
Large T Antigen (dilution 1:100; BD Biosciences), or anti-synaptophysin (undiluted; 
Lifespan Biosciences). After washing, the slides were incubated with anti-rabbit 
Alexa488 (Invitrogen), anti-rabbit-Cy3 (Dianova, Hamburg, Germany), anti-mouse 
Alexa555, or anti-mouse Alexa488 (both from Cell Signaling Technology), washed 
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again and incubated with DAPI (Invitrogen). Finally, the slides were washed, 
mounted with fluorescence mounting medium (DAKO) and analyzed using a Zeiss 
Axiovert 200 microscope (Zeiss) with the Visiview software (Visitron Systems, 
Puchheim, Germany).  
Fresh frozen cryostat sections of whole pancreata were stained as described36. 
Briefly, the sections were fixed with periodate-lysine-paraformaldehyde, blocked with 
donkey serum (dilution 1:20), and then incubated with rabbit anti-pHP1γ (dilution 
1:80), mouse anti-PCNA (dilution 1:50), mouse anti-p16Ink4a (dilution 1:50), or rabbit 
anti-Ki67 antibodies (dilution 1:100). After washing, the sections were incubated with 
Cy3-conjugated donkey anti-rabbit, donkey anti-mouse, or Cy5-conjugated donkey-
anti-rabbit, donkey-anti-mouse IgG (all from Dianova). Before mounting the slides 
with Mowiol (Hoechst, Frankfurt, Germany), nuclei were stained with Yopro (1:2000; 
Invitrogen). The sections were analyzed using a Leica TCS-Sp/Leica DM RB 
confocal laser scanning microscope (Leica Microsystems). Images were processed 
with the Leica Confocal Software LCS (Version 2.61).  
Formalin-fixed pancreata were embedded in paraffin. Sections (3-5 µm thick) were 
cut and stained with H&E. Immunohistochemistry was performed on an automated 
immunostainer (Ventana Medical System, Tucson, AZ, USA), according to the 
manufacturer’s protocol, with minor modifications37. The antibody panel used 
included activated caspase-3 (Cell Signaling Technology), Ki-67 (DCS Innovative 
Diagnostic Systeme, Hamburg, Germany), pHP1-γ (Abcam), and H3K9me3 (Cell 
Signaling Technology). 
SA-β-galactosidase activity assay. Cancer cells were fixed for 15 min at RT, and 
then stained for 16 h at 37°C using the β-Galactosidase Staining Kit (United States 
Biological; Swampscott, MA, USA). SA-β-gal-positive and -negative cells were then 
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counted using a Zeiss Axiovert 200 microscope (Zeiss). In some experiments, the 
cells were counterstained for synaptophysin by immunofluorescence, and 
synaptophysin/SA-β-gal double-positive cells were counted. 
Cell cycle analysis. After treatment of β-cancer cells, cell cycle analysis was 
performed using the BD PharmingenTM FITC-BrdU Flow Kit according to the 
manufacturer´s protocol (BD Biosciences). The samples were analyzed by flow 
cytometry on a LSR II from Becton Dickinson (Heidelberg, Germany), and the 
following cell cycle phases were determined in % of the total population:  subG1 
(apoptotic cells), G1/G0 (2n, BrdU-negative), S (2n-4n, BrdU-positive) and G2/M 
phase (4n, BrdU-negative). 
Western blot. After treatment, cancer cells were lysed in lysis buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% SDS, 1mM NaF, 1mM Na3VO4, 
and 0.4% β-mercaptoethanol) containing a protease inhibitor cocktail and a 
phosphatase inhibitor cocktail (PhosSTOP from Roche Diagnostics). Alternatively, 
cytoplasmic protein extracts were obtained from the cell cultures using the NE-PER 
extraction kit (Thermo Fisher Scientific, Rockford, IL, USA) according to the 
manufacturer´s protocol. Before use, protease inhibitors and PhosSTOP were added 
to the lysis buffers CER I and NER. After determination of protein content by the 
bicinchoninic acid assay (BCA; Thermo Fisher Scientific), proteins were resolved by 
12% SDS-PAGE or by Mini Protean TGX Precast Gels (4-15%; from BioRad, 
München, Germany), transferred onto a PVDF membrane and blocked with 3% 
nonfat milk in TBS/0.1% Tween 20 (TBST) as described38. The membrane was 
incubated with anti-p16Ink4a (1:1000; Santa Cruz), anti-Rb (Ab-780) (1:1000), anti-
Rb(phospho-Ser-795) (1:1000; both from SAB Signalway Antibody, Pearland, TX, 
USA), or anti-β-actin antibody (1:1000; BioVision, Mountain View, CA, USA). After 
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washing with TBST and subsequent blocking, the blots were incubated with goat 
anti-mouse horseradish-peroxidase (HRP)-conjugated antibody or with goat anti-
rabbit horseradish-peroxidase (HRP)-conjugated antibody (1:3000; Cell Signaling 
Technology), washed again and antibody binding was detected with the ECL 
detection reagent (Amersham, Freiburg, Germany). Immunoreactive bands were 
quantified using the ImageJ software (National Institute of Health, Bethesda, MD, 
USA), and the phospho-Rb/Rb ratio of the samples was calculated.  
Statistics. Data are expressed as arithmetic means ± S.E.M. and statistical analyses 
were made by unpaired t-test, or ANOVA using Dunnett´s or Tukey´s test as post hoc 
test, where appropriate. P<0.05 was considered statistically different. 
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